Galanthamine improves myocardial ischemia-reperfusion-induced cardiac dysfunction, endoplasmic reticulum stress-related apoptosis, and myocardial fibrosis by suppressing AMPK/Nrf2 pathway in rats

Xiaolin Hou¹, Minhuan Fu², Biao Cheng², Yu Kang³, Dili Xie²

¹Department of Cardiology, ²Department of Geriatric Cardiology, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Chengdu 610072, China; ³Department of Cardiology, West China Medical College, Sichuan University, Chengdu 610065, China

Contributions: (I) Conception and design: X Hou, M Fu; (II) Administrative support: X Hou; (III) Provision of study materials or patients: X Hou, M Fu, B Cheng, Y Kang, D Xie; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: X Hou, M Fu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dili Xie. Department of Geriatric Cardiology, Sichuan Provincial People’s Hospital, No. 18, Section 3, Renmin South Road, Chengdu 610072, China. Email: ilg7ky21bjehr@sina.com.

Background: Myocardial ischemia/reperfusion (I/R) injury is an important cause of myocardial infarction and heart failure after cardiovascular surgery. Galanthamine (Gal) is an important Amaryllidaceae alkaloid with anti-acetylcholinesterase and anti-inflammatory activity. The purpose of this study was to investigate the role of Gal in myocardial I/R injury.

Methods: In this study, an animal model of myocardial I/R injury was constructed, and the rats were divided into five groups (n=10): the sham, I/R model, I/R + Gal (1 mg/kg), I/R + Gal (3 mg/kg), and I/R + Aspirin (20 mg/kg) groups. The expression of related proteins was detected by Western blotting and Immunohistochemistry, and Histological lesion was detected by HE staining.

Results: Results showed that Gal improves I/R—induced cardiac dysfunction in rats. Moreover, Gal inhibits I/R—induced endoplasmic reticulum stress (ERS)-related apoptosis by suppressing the expression of CHOP, Cleaved caspase 12, and caspase 3, and promoting the expression of CADD34 and BiP in rats. Furthermore, Gal mitigates I/R—induced myocardial fibrosis through restraining the expression of α-SMA and Collagen I in rats. Mechanically, Gal promoted the expression of AMPKα1, Nrf2 and HO-1. However, AMPK inhibitor Compound C exhibited the opposite effects. Collectively, this finding suggests that Gal improves I/R-induced cardiac dysfunction, ERS-related apoptosis, and myocardial fibrosis by activating AMPK/Nrf2 pathway in myocardial I/R rats.

Conclusions: Given this evidence, Gal may be a potential therapeutic drug for the treatment of I/R injury.

Keywords: Myocardial ischemia/reperfusion injury; galanthamine, endoplasmic reticulum stress; adenosine-activated protein kinase; nuclear factor erythroid-2-related factor 2

Submitted Sep 10, 2019. Accepted for publication Sep 23, 2019.
doi: 10.21037/atm.2019.10.108
View this article at: http://dx.doi.org/10.21037/atm.2019.10.108

Introduction

Myocardial ischemia does a certain degree of damage to the function, morphology, and metabolism of cardiomyocytes (1). Restoring blood reperfusion is the most effective way to reduce myocardial ischemia injury. However, the restoration of blood reperfusion will aggravate the damage of cardiomyocyte
function, structure, and metabolism; i.e., myocardial ischemia/reperfusion (I/R) injury (2). Myocardial I/R injury is a major cause of myocardial infarction and heart failure after cardiovascular surgery (3). With the help of mechanical or drug intervention, the rapid recovery of blood supply through an occlusive coronary artery is the most effective treatment for ischemia (4). However, the mechanism of myocardial I/R injury is very complex (5). Myocardial I/R injury has become a major obstacle in the clinical treatment of ischemic cardiomyopathy (6). Therefore, it is very important to clarify the mechanism of myocardial I/R and to find drugs against myocardial I/R injury for the treatment of ischemic cardiomyopathy.

Galanthamine (Gal) is an important Amaryllidaceae alkaloid with anti-acetylcholinesterase and anti-inflammatory activity (7). As an acetylcholinesterase inhibitor, Gal has been approved as a long-acting anti-cholinesterase drug for the treatment of Alzheimer’s disease (AD) (8). The choline-like drugs such as Gal have an effect on the GCI/R injury caused by low cholinergic function (9). Activation of the neuronal or non-neuronal cholinergic pathway in the heart reduces ischemic injury and plays an important role in improving cardiac systolic function and reducing infarct size (10). This study elucidated the role and potential molecular mechanisms of Gal in myocardial I/R.

The endoplasmic reticulum (ER) is a dynamic and stable organelle involved in the synthesis of proteins and lipids and the regulation of Ca²⁺ concentration (11). Cells exposure to hypoxia or certain chemotherapeutic drugs can cause accumulation of unfolded proteins and changes in calcium homeostasis, leading to endoplasmic reticulum stress (ERS) (12). Under stress conditions, ERS activates adenosine-activated protein kinase (AMPK), a metabolically sensitive protein kinase that regulates cell homeostasis and reprogramming of metabolism. ERS also induces nuclear factor erythroid 2 related factor 2 (Nrf2) nuclear translocation in a PERK-dependent manner without the involvement of subunit eukaryotic translation initiation factor 2 (eIF2a) or ROS accumulation (13,14). Under stress conditions, activation of AMPK and Nrf2 reduces myocardial I/R injury and improves cardiac function (15,16).

This study constructed an animal model of myocardial I/R injury and investigated the role of Gal in myocardial I/R injury along with the potential mechanism involved. The results found that Gal improves I/R-induced cardiac dysfunction, ERS-related apoptosis, and myocardial fibrosis by suppressing AMPK/Nrf2 pathways in myocardial I/R rats. This study indicates that Gal may be a potential therapeutic drug for the treatment of I/R injury.

Methods

Construction of myocardial I/R rat model

All animal experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Medical Ethics Committee of Sichuan Provincial People’s Hospital. A total of 50 Sprague-Dawley (SD) rats (male, weight 220–280 g) were obtained from the Animal Center of Sichuan Provincial People’s Hospital and housed in a controlled environment at 25±3 ℃, with a humidity of 60%, in a 12-h light/dark cycle with free access to water. Rats were grouped into five groups (10 in each group): the sham, I/R model, I/R + Gal (1 mg/kg), I/R + Gal (3 mg/kg), and I/R + Aspirin (20 mg/kg) group. The rats in the sham group and I/R group were slowly injected with normal saline 30 min before the establishment of the model. The rats in I/R + Gal (1 mg/kg) and I/R + Gal (3 mg/kg) group were injected with Gal (1 and 3 mg/kg). The rats in I/R + Aspirin (20 mg/kg) group were injected with Aspirin (20 mg/kg). A myocardial I/R rat model was prepared by a method described by Ahmed et al. (17). Rats were anesthetized by intraperitoneal injection of chloral hydrate (10%) and fixed in the supine position. The pericardium of the rat was cut open to expose the heart. A 4-0 suture needle was passed through 2 to 3 mm below the left atrial appendage, and a 1.5 mm diameter latex tube was placed under the ligature. Tightening the ligature blocks the blood flow to the coronary arteries to cause myocardial ischemia. After half an hour, the ligature was released and a 2 h blood perfusion was performed to form a model of ischemia-reperfusion injury. The changes of left ventricular ejection fraction (LVEF), shortening fraction (FS), left ventricular wall thickness (LVWT), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV) were detected by echocardiography.

Western blotting

Myocardial tissues were lysed in lysis buffer (Beyotime, Shanghai, China) containing protease and phosphatase inhibitor. Proteins (20 μg) were separated by 10% SDS-PAGE and transferred to a PVDF membrane. Subsequently,
the membranes were blocked with 5% skim milk powder and incubated overnight at 4 °C with primary antibodies against CHOP (#2895, 1:1000, Cell Signaling Technology, Beverly, MA, USA), Cleaved caspase 12 (#2202, 1:1000, CST, Beverly, MA, USA), GADD34 (ab9869, 1:5000, Abcam, Cambridge, UK), Bip (#3177, 1:1000, CST, Beverly, MA, USA), Actin (ab179467, 1:5000, Abcam, Cambridge, UK), α-SMA (#19245, Cleaved caspase-12 (#2202, 1:1000, CST, Beverly, MA, USA), Bcl-2 (#14796, 1:1000, CST, Beverly, MA, USA), Bax (#14796, 1:1000, CST, Beverly, MA, USA), Bip (#3177, 1:1000, CST, Beverly, MA, USA), Actin (ab179467, 1:5000, Abcam, Cambridge, UK), α-SMA (#19245, 1:1000, CST, Beverly, MA, USA), Collage 1 (ab34710, 1:5000, Abcam, Cambridge, UK), AMPKα (ab32047, 1:5000, Abcam, Cambridge, UK), Nrf2 (ab137550, 1:5000, Abcam, Cambridge, UK), and HO-1 (ab13243, 1:5000, Abcam, Cambridge, UK). Then, the membranes were washed with TBST, incubated with secondary antibodies (Abcam, Cambridge, UK) for 1.5 h at room temperature, and detected using ECL kit (Millipore Corp, Bedford, MA, USA).

Quantitative real-time PCR

Total RNA was extracted from myocardial tissues using RNAprep pure Tissue Kit (Tiangen, Beijing, China) and reversed transcribed into cDNA using FastKing gDNA Dispelling RT SuperMix according to the manufacturer’s instructions. Quantitative real-time PCR was performed using a FastFire qPCR PreMix (SYBR Green) on a 7500 Real-Time PCR System (Applied Biosystems, USA). Primer sequences were as follows: Caspase 3, S, 5′-TCGACTAGCAATGCTGACGC-3′; AS, 5′-CATCGACATCGCTACACAATCG-3′.

Immunohistochemistry

Immunohistochemistry was conducted to detect the expression of caspase 3 in myocardial tissues. Briefly, the slices were deparaffinized with xylene and hydrated with gradient ethanol. Then, the slices were incubated with the primary antibody caspase 3 (#14214, 1:1000, CST, Beverly, MA, USA), treated with a universal secondary antibody (#7074, CST, Beverly, MA, USA), and counterstained with hematoxylin. The number of caspase 3—positive cells was counted and expressed as an average number.

Haematoxylin and eosin (H&E) staining

Myocardial tissues were fixed in 4% paraformaldehyde for 48 h. Then, the tissues were ethanol-dehydrated, paraffin-embedded, and sectioned into slices (5 μm). Subsequently, the slices were stained with H&E for histological assay.

Statistical analysis

The data are expressed as mean ± SEM, and SPSS 17.0 (SPSS, Chicago, IL, USA) was applied to determine statistical significance by unidirectional ANOVA. P<0.05 was considered to be statistically significant.

Results

Gal improves I/R—induced cardiac dysfunction in rats

The results found that compared with the sham group, the I/R group had LVWT, FS, and LV EF significantly decrease from 0.75±0.05, 27±4.22, and 53%±6.15% to 0.61±0.03, 13±2.61, and 29%±7.08%, respectively, while LVEDV (μL) and LVESV (μL) were significantly increased from 56±7.32 and 31±4.66 to 82±7.50 and 53±6.27, respectively. Interestingly, after Gal treatment, the levels of LVWT, FS, and LV EF were significantly increased in a dose-dependent manner from 0.61±0.03, 13±2.61, and 29%±7.08% to 0.71±0.04, 22±4.15, and 45%±6.19%, respectively, while the levels of LVEDV (μL) and LVESV (μL) were significantly reduced from 82±7.50 and 53±6.27 to 64±6.11 and 41±4.02, respectively (Figure 1). A similar effect was observed after treatment with Aspirin. These results indicate that Gal, like Aspirin, improves I/R-induced cardiac dysfunction in rats.

Gal inhibits I/R—induced apoptosis by suppressing endoplasmic reticulum pathway in rats

We then investigated the roles of Gal in I/R—induced apoptosis. The results showed that, compared with the sham group, I/R treatment significantly promoted the activation of ERS-related pro-apoptotic molecules (CHOP and Cleaved caspase-12), while inhibiting the expression of ERS-associated pro-survival molecules (GADD34 and BiP) (Figure 2A,B). Moreover, RT-qPCR and IHC analysis showed that I/R treatment also promoted the expression of caspase 3 in myocardial tissues. Interestingly, Gal treatment dose-dependently inhibited the activation of CHOP and Cleaved caspase-12, while promoting the expression of GADD34 and BiP. At the same time, Gal treatment also promoted the expression of caspase 3 in myocardial tissues in a dose-dependent manner. Similar results were obtained...
when treating I/R rats with Aspirin (Figure 2C, D). These results indicate that Gal inhibits I/R-induced apoptosis by suppressing endoplasmic reticulum pathway in rats.

**Gal mitigates I/R—induced myocardial fibrosis in rats**

H&E staining was employed to investigate the effect of Gal on I/R—induced myocardial fibrosis. The results showed that compared with Sham group, myocardial fibers in the myocardial tissue of the I/R group were arranged in a disorderly fashion and accompanied by nuclear pyknosis. Myocardial tissue was dropsical, and the myocardial space was enlarged. After Gal treatment, the degrees of myocardial fiber disorder and interstitial edema in rat myocardial tissue were improved in a dose-dependent manner compared with the I/R group. Similar effects were observed in the Aspirin group (Figure 3A). Additionally, western blotting analysis showed that I/R treatment significantly promoted the expression of cardiac fibroblast activation markers α-SMA and Collagen I. Interestingly, Gal treatment, like Aspirin, dose-dependently counteracted the effect of I/R on the expression of α-SMA and Collagen I (Figure 3B). These results indicate that Gal mitigates I/R—induced myocardial fibrosis in rats.

**Gal improves myocardial I/R injury by activating AMPK/Nrf2 pathway**

To investigate the potential molecular mechanism, western blotting was performed. As shown in Figure 4A, I/R treatment significantly inhibited the expression of AMPKα1 and Nrf pathway–associated proteins (Nrf2 and HO-1) compared to the sham group. However, Gal treatment dose-dependently reversed the inhibitory effect of I/R on AMPKα1, Nrf2, and HO-1 expression. These results are similar to those after aspirin treatment of I/R (Figure 4A). To further verify that the AMPK pathway is involved in the role of Gal, the AMPK pathway inhibitor Compound C (CC) was applied. As shown in Figure 4B, in contrast to Gal, the addition of CC further inhibited the expression of AMPKα1. Functionally, the addition of CC also aggravates the effects of I/R on cardiac dysfunction, ERS-induced apoptosis, and myocardial fibrosis (Figure 4C, D, E, F). Collectively, these results demonstrate that Gal improves myocardial I/R injury by regulating AMPK/Nrf2 pathway.

**Discussion**

I/R can cause oxidative stress and energy metabolism...
disorder in myocardial tissue, which in turn leads to cardiomyocyte injury, apoptosis, or necrosis (18,19). In addition, it can further induce the activation of ER-specific apoptosis protein Caspase-12 and suppress the expression of CHOP and other proteins by regulating calcium balance to induce endoplasmic reticulum stress (18,20-22). In this study, it was found that after myocardial I/R treatment, LVWT, FS, and LVEF decreased significantly, while LVEDV and LVESV increased significantly. Also, myocardial I/R treatment accelerated the expression of apoptosis-promoting proteins CHOP and Cleaved caspase-12 in the endoplasmic reticulum, and inhibited the expression of survival-promoting molecules GADD34 and BiP, which promoted apoptosis induced by endoplasmic reticulum stress. In addition, myocardial I/R treatment promoted myocardial fibrosis by promoting the expression of α-SMA and Collagen I. These results suggest that myocardial I/R leads to myocardial injury by aggravating cardiac dysfunction, accelerating endoplasmic reticulum stress cell apoptosis, and promoting myocardial fibrosis.

On the one hand, as an acetylcholinesterase inhibitor

Figure 2 Gal inhibits I/R—induced apoptosis by suppressing endoplasmic reticulum pathway in rats. Rats were grouped into five groups (10 in each group): Sham group, I/R model, I/R + Gal (1 mg/kg), I/R + Gal (3 mg/kg), and I/R + Aspirin (20 mg/kg) group. (A) The protein levels of CHOP and Cleaved caspase 12 were measured by western blotting assay; (B) the protein levels of GADD34 and BiP were measured by western blotting assay; (C) the mRNA level of Caspase 3 was measured by RT-qPCR; (D) the expression of caspase 3 in myocardial tissues was detected by IHC assay. Actin was used as an internal reference. *, P<0.05 vs. sham group; #, P<0.05 vs. I/R group.
(AChEI), Gal is widely used in the treatment of Alzheimer's disease and other dementia (23,24). Previous studies have shown that Gal can improve behavioral flexibility disorder and cortical injury caused by traumatic brain injury (25). In addition, Gal has been observed reversing the cognitive impairment of mice after operation, reducing the levels of microglia and inflammatory factors (IL-1β, IL-6) in hippocampus, and normalizing early POCD by enhancing cholinergic nerve tension in the hippocampus (26). For one, as a positive allosteric regulator of nicotine acetylcholine receptor (NACHRs), Gal plays an important role in protecting muscarinic and nicotine receptor functions and improving global cerebral ischemia/reperfusion (GCI/R) injury (9). For another, Gal can reduce ischemic injury by protecting muscarinic acetylcholine receptors and activating neuronal or non-neuronal cholinergic pathways in the heart. Furthermore, Gal can inhibit Abeta-induced apoptosis of PC12 cells by improving mitochondrial dysfunction and reducing endoplasmic reticulum stress (27). On this basis, current studies have found that Gal can improve cardiac dysfunction induced by myocardial I/R in a dose-dependent manner, inhibit the expression of endoplasmic reticulum apoptosis-related proteins (CHOP and Cleaved caspase-12) and caspase 3, and promote the expression of GADD34 and BiP to improve endoplasmic reticulum stress cell apoptosis. Further to this, our study also found that Gal can improve myocardial fibrosis by inhibiting the expression of α-SMA and Collagen I. These results suggest that Gal can improve cardiac dysfunction, apoptosis, and myocardial fibrosis caused by myocardial I/R.

Long-term ERS induces ERS-related apoptosis (28). I/R can cause myocardial damage by inducing excessive myocardial ERS (29). Therefore, detecting the expression of the endoplasmic reticulum-associated proteins may reflect the effect of I/R on ERS-induced apoptosis. In our study, I/R was found to significantly promote the expression of CHOP and Cleaved caspase 12, while inhibiting the expression of GADD34 and BiP, indicating that I/R induces ERS-related apoptosis. MAPK, PI3K/AKT, PERK, JAK/STAT3, AMPK, and Nrf2 signaling pathways are involved in I/R-induced ERS (30-35). Among them, the activation of AMPK and Nrf2 signaling pathways has a significant

Figure 3 Gal mitigates I/R—induced myocardial fibrosis in rats. Rats were grouped into five groups (10 in each group): Sham group, I/R model, I/R + Gal (1 mg/kg), I/R + Gal (3 mg/kg), and I/R + Aspirin (20 mg/kg) group. (A) Myocardial fibrosis was determined by H&E staining (magnification: 400×). (B) The protein levels of α-SMA and collagen I were measured by western blotting assay. Actin was used as an internal reference. *, P<0.05 vs. sham group; #, P<0.05 vs. I/R group.
Figure 4 Gal improves myocardial I/R injury by activating AMPK/Nrf2 pathway. (A) Rats were grouped into five groups (10 in each group): Sham group, I/R model, I/R + Gal (1 mg/kg), I/R + Gal (3 mg/kg), and I/R + Aspirin (20 mg/kg) group. The protein levels of AMPKα1, Nrf2, and HO-1 were measured by western blotting assay. Actin was used as an internal reference. *, P<0.05 vs. sham group; #, P<0.05 vs. I/R group. (B,C,D,E,F) Rats were grouped into five groups (10 in each group): Sham group, I/R model, I/R + Gal (3 mg/kg), I/R + CC (200 μM), and I/R + Gal (3 mg/kg) + CC (200 μM) group. (B) The protein levels of AMPKα1, Nrf2, and HO-1 were measured by western blotting assay. (C) LVESV and FS. (D) The protein levels of CHOP and BiP were measured by western blotting assay. (E) The mRNA level of Caspase 3 was measured by RT-qPCR. (F) The protein levels of α-SMA and collagen I were measured by western blotting assay. Actin was used as an internal reference. *, P<0.05 vs. sham group; #, P<0.05 vs. I/R group; &, P<0.05 vs. I/R + CC group.
improvement on myocardial damage caused by I/R. Feng et al. found that schisandra can significantly improve cardiac function, reduce apoptosis, inhibit ERS, and attenuate MI/R-induced myocardial damage by activating AMPK signaling pathway (34). In addition to this, Zhang et al. found that ghrelin, a cardioprotective peptide, protects the heart from ischemia/reperfusion (I/R) injury by activating the AMPK signaling pathway and inhibiting endoplasmic reticulum stress (ERS)-induced damage and apoptosis (36). Similarly, Hou et al. found that hyperoside (Hyp) increased myocardial ATP levels, reduced myocardial oxidative damage, and reduced cardiomyocyte apoptosis by activating the Nrf2 signaling pathway (37). Moreover, Wang et al. found that Crocin attenuated I/R-induced ERS, left ventricular dysfunction and myocardial infarction in mice by inhibiting the miR-34a/Sirt1/Nrf2 pathway (35). Similar to the above results, this study found that I/R inhibited the expression of AMPK and Nrf2-related proteins (AMPKα1, Nrf2 and HO-1). Interestingly, Gal treatment promoted the activation of the AMPK and Nrf2 pathways in a dose-dependent manner, thereby improving I/R-induced cardiac dysfunction, endoplasmic reticulum stress-related apoptosis, and myocardial fibrosis.

Collectively, Gal improves I/R-induced cardiac dysfunction, ERS-related apoptosis, and myocardial fibrosis by suppressing AMPK/Nrf2 pathways. Overall, these findings support the use of Gal as a potential therapeutic drug for the treatment of I/R injury.

**Acknowledgments**

None.

**Footnote**

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All animal experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Medical Ethics Committee of Sichuan Provincial People’s Hospital.

**References**


